I'm calling it..., page-61

to CarringtonLangford,

mate, I reckon it needs to be on this thread:

"The more time I have spent researching MSB and its stem cell product pipeline the more impressed I am as I feel the company is on the cutting edge of 21st century biological technology that will totally revolutionise the treatment of a host of diseases and ailments. MSB is specifically targeting cardiac diseases, spine orthopedic disorders, oncology and hematology diseases, and immune-mediated and inflammatory conditions.
I am absolutely astounded with how advanced the company is with their portfolio of cell-based products which include five programs in active Phase 3 clinical studies or Phase 3-ready, and four programs in Phase 2. MSB appears to be one of the companies at the vanguard of this blockbuster technology, which only a score ago was the stuff of dreams and science fiction. I have had a good look at the qualifications and experience of the board of directors and management team and have to say I am very impressed. I will be buying in."